RZRen-Dan Zhang

Ren-Dan Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ren-Dan Zhang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Successful use of immunoadsorption therapy in advanced dilated cardiomyopathy: A case report

    by Rendan Zhang, Lvwen Ning, Ying Liu, Zhixiong Tan, Lu Kong, Xiaoqing Quan, Xiehui Chen

    Rationale: Dilated cardiomyopathy (DCM) is a major cause of chronic heart failure, and some patients continue to deteriorate despite guideline-directed medical therapy. Immunoadsorption (IA), which removes pathogenic autoantibodies, has been proposed as a potential adjunctive therapy, but its clinical use remains limited. This case illustrates the potential benefits of IA in advanced, treatment-refractory DCM. Patient concerns: A 53-year-old woman with a 9-year history of DCM presented with recurrent chest tightness and dyspnea. Despite long-term guideline-directed medical therapy, her symptoms progressively worsened. Diagnoses: The patient had chronic DCM initially diagnosed in the peripartum period, with a left ventricular ejection fraction (LVEF) of 11% at onset. Before IA, echocardiography demonstrated severe systolic dysfunction (LVEF 22%–24%) with significant mitral regurgitation, and laboratory evaluation showed markedly elevated pro-BNP (4454 pg/mL). Interventions: The patient underwent two sessions of immunoadsorption in September 2024, followed by high-dose intravenous immunoglobulin (IVIG) as per standard protocols. Outcomes: Following treatment, her symptoms improved, pro-BNP decreased to 2109 pg/mL, and repeat echocardiography showed an increase in LVEF to 29.2%. Lessons: This case suggests that immunoadsorption may offer clinical benefit in patients with advanced, refractory DCM. While promising, IA remains experimental and requires further investigation in larger, controlled studies.

  • Open Access

    Left atrial myxoma complicated with multi-system embolization

    by Ren-Dan Zhang, Zhi-Huan Zeng, Jian-Yi Zheng, Tu-Di Li, Yan-Qun Zhao, Yu-Hong Liu, Yu-Si Yao

    Atrial myxoma accounts for approximately 50% of all cardiac tumors. The majority of myxomas are located in the left atrium and present variable clinical manifestation. A young man was transferred to our hospital with sudden onset of resting pain, pallor and numb in right leg. An atrial mobile mass was detected by transthoracic echocardiography. Anticoagulant and antithrombotic therapy were administered, a timely surgery was performed and the mass was confirmed as a myxoma. The patient did not discharge any discomfort post-operation. For patients with atrial myxoma, early diagnosis is essential, anticoagulant or antithrombotic therapy and surgery have a great importance to prevent further embolism.